| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.12 | 0.5 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.5 |